dexchlorpheniramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4411	25523-97-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexchlorpheniramine (+)-Chloropheniramine (+)-Chlorpheniramine S-Chlorpheniramine d-Chlorpheniramine dexchlorpheniramine maleate	Molecular weight: 274.79 Formula: C16H19ClN2 CLOGP: 3.15 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 16.13 ALOGS: -3.72 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexchlorpheniramine
(+)-Chloropheniramine
(+)-Chlorpheniramine
S-Chlorpheniramine
d-Chlorpheniramine
dexchlorpheniramine maleate

Molecular weight: 274.79
Formula: C16H19ClN2
CLOGP: 3.15
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 16.13
ALOGS: -3.72
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
6	mg	O
6	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 14, 1981	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Erythema	348.91	26.12	227	6642	146187	50452068
Infusion related reaction	188.51	26.12	167	6702	169390	50428865
Hypersensitivity	154.79	26.12	167	6702	214994	50383261
Hepatocellular injury	140.12	26.12	69	6800	25878	50572377
Anaphylactic shock	119.04	26.12	57	6812	20098	50578157
Sense of oppression	91.35	26.12	22	6847	923	50597332
Oxygen saturation decreased	78.79	26.12	71	6798	73177	50525078
Cytokine release syndrome	78.39	26.12	33	6836	8601	50589654
Pyrexia	75.82	26.12	162	6707	380041	50218214
Febrile neutropenia	75.58	26.12	79	6790	97588	50500667
Rash maculo-papular	62.27	26.12	41	6828	26600	50571655
Hyperthermia	58.67	26.12	26	6843	7670	50590585
Dyspnoea	58	26.12	184	6685	547424	50050831
Neutrophil count decreased	56.25	26.12	48	6821	45978	50552277
Drug ineffective	54.15	26.12	22	6847	819311	49778944
Hypertension	52.73	26.12	99	6770	211104	50387151
Fatigue	51.84	26.12	16	6853	707585	49890670
Chest discomfort	51.24	26.12	63	6806	92659	50505596
Hypotension	44.08	26.12	98	6771	235371	50362884
Wrong patient received product	39.65	26.12	13	6856	1687	50596568
Pruritus	39.19	26.12	105	6764	283463	50314792
Cholestasis	38.40	26.12	30	6839	25371	50572884
Feeling hot	38.22	26.12	36	6833	39166	50559089
Bronchospasm	37.50	26.12	24	6845	14830	50583425
Hepatic function abnormal	35.72	26.12	32	6837	32649	50565606
Tachycardia	34.36	26.12	54	6815	99709	50498546
Chills	32.83	26.12	52	6817	96635	50501620
Platelet count decreased	32.60	26.12	53	6816	100673	50497582
Urticaria	32.59	26.12	61	6808	129500	50468755
Lymphopenia	31.62	26.12	22	6847	15599	50582656
Malaise	31.08	26.12	108	6761	335424	50262831
Serum sickness	30.99	26.12	12	6857	2520	50595735
Psychiatric decompensation	30.88	26.12	10	6859	1248	50597007
Cytomegalovirus infection	28.86	26.12	22	6847	17940	50580315
Febrile bone marrow aplasia	28.81	26.12	15	6854	6296	50591959
Pain	28.81	26.12	22	6847	578881	50019374
Persecutory delusion	28.11	26.12	11	6858	2376	50595879
Anaphylactoid reaction	27.55	26.12	12	6857	3394	50594861
Mixed liver injury	27.40	26.12	12	6857	3439	50594816

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile bone marrow aplasia	138.37	22.54	55	6754	7296	29560422
Infusion related reaction	130.79	22.54	96	6713	43790	29523928
Erythema	122.15	22.54	116	6693	75490	29492228
Hypersensitivity	121.17	22.54	99	6710	52804	29514914
Febrile neutropenia	105.04	22.54	129	6680	112111	29455607
Cytokine release syndrome	85.17	22.54	47	6762	13072	29554646
Anaphylactic shock	76.34	22.54	44	6765	13292	29554426
Alveolar lung disease	73.19	22.54	17	6792	352	29567366
Pulmonary interstitial emphysema syndrome	69.24	22.54	17	6792	449	29567269
Generalised oedema	67.02	22.54	38	6771	11127	29556591
Pyrexia	66.17	22.54	179	6630	287443	29280275
Hyperthermia	56.33	22.54	32	6777	9398	29558320
Neutropenia	51.22	22.54	101	6708	131610	29436108
Diffuse alveolar damage	48.10	22.54	18	6791	2025	29565693
Chills	45.26	22.54	68	6741	71232	29496486
Face oedema	43.59	22.54	28	6781	10255	29557463
Kounis syndrome	42.64	22.54	16	6793	1813	29565905
Hyperammonaemia	41.50	22.54	22	6787	5641	29562077
Fatigue	41.42	22.54	11	6798	316810	29250908
Sense of oppression	39.48	22.54	11	6798	480	29567238
Eosinophilic pneumonia	39.03	22.54	17	6792	2829	29564889
Necrotising retinitis	38.80	22.54	12	6797	756	29566962
Interstitial lung disease	35.12	22.54	54	6755	57664	29510054
Cytomegalovirus test positive	32.98	22.54	16	6793	3407	29564311
Oxygen saturation decreased	31.59	22.54	45	6764	44892	29522826
Cardiac ventricular disorder	31.57	22.54	8	6801	241	29567477
Disseminated intravascular coagulation	30.90	22.54	30	6779	19950	29547768
Abdominal compartment syndrome	29.67	22.54	10	6799	829	29566889
Malaise	29.41	22.54	92	6717	159510	29408208
Platelet count decreased	28.90	22.54	70	6739	104602	29463116
Rash	28.41	22.54	102	6707	189717	29378001
Hypoxia	28.36	22.54	44	6765	47335	29520383
Acute coronary syndrome	28.00	22.54	23	6786	12302	29555416
Cytomegalovirus infection	27.14	22.54	30	6779	23185	29544533
Blood immunoglobulin G decreased	26.51	22.54	10	6799	1149	29566569
Drug ineffective	26.33	22.54	27	6782	363143	29204575
Tumour lysis syndrome	25.61	22.54	23	6786	13861	29553857
Neutrophil count decreased	25.43	22.54	40	6769	43527	29524191
Eosinophilia	24.81	22.54	28	6781	22133	29545585
Rash maculo-papular	24.37	22.54	29	6780	24260	29543458
Urticaria	23.73	22.54	44	6765	54616	29513102
White blood cell count decreased	23.26	22.54	56	6753	83306	29484412
Pruritus	23.02	22.54	69	6740	116780	29450938
Hepatic function abnormal	22.84	22.54	36	6773	39223	29528495

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Erythema	420.37	19.66	335	13446	186735	64298216
Infusion related reaction	305.44	19.66	264	13517	164203	64320748
Hypersensitivity	254.18	19.66	258	13523	196194	64288757
Anaphylactic shock	169.55	19.66	96	13685	30232	64454719
Febrile neutropenia	156.01	19.66	196	13585	187461	64297490
Cytokine release syndrome	147.15	19.66	77	13704	20752	64464199
Febrile bone marrow aplasia	129.13	19.66	58	13723	11197	64473754
Hepatocellular injury	127.48	19.66	93	13688	45142	64439809
Sense of oppression	121.47	19.66	33	13748	1414	64483537
Pyrexia	121.46	19.66	325	13456	558319	63926632
Hyperthermia	105.60	19.66	56	13725	15494	64469457
Oxygen saturation decreased	90.57	19.66	113	13668	107063	64377888
Fatigue	85.59	19.66	27	13754	748703	63736248
Rash maculo-papular	76.06	19.66	70	13711	46956	64437995
Chills	75.89	19.66	118	13663	137146	64347805
Neutrophil count decreased	74.35	19.66	87	13694	77109	64407842
Pulmonary interstitial emphysema syndrome	70.60	19.66	17	13764	446	64484505
Alveolar lung disease	68.10	19.66	17	13764	520	64484431
Toxicity to various agents	65.11	19.66	3	13778	363510	64121441
Drug ineffective	64.95	19.66	51	13730	840196	63644755
Hypertension	62.33	19.66	157	13624	259104	64225847
Platelet count decreased	61.12	19.66	120	13661	167591	64317360
Neutropenia	55.39	19.66	143	13638	239481	64245470
Hepatic function abnormal	54.59	19.66	68	13713	64245	64420706
Pruritus	51.43	19.66	165	13616	312235	64172716
Generalised oedema	50.11	19.66	39	13742	20814	64464137
Dyspnoea	49.93	19.66	292	13489	718382	63766569
Malaise	49.47	19.66	191	13590	396056	64088895
Face oedema	48.29	19.66	41	13740	24720	64460231
Feeling hot	48.22	19.66	54	13727	45609	64439342
Hypotension	47.85	19.66	184	13597	380790	64104161
Interstitial lung disease	47.12	19.66	79	13702	97653	64387298
White blood cell count decreased	47.03	19.66	104	13677	157733	64327218
Bronchospasm	46.64	19.66	38	13743	21644	64463307
Cytomegalovirus infection	46.32	19.66	48	13733	37151	64447800
Urticaria	46.09	19.66	99	13682	147218	64337733
Tumour lysis syndrome	45.93	19.66	36	13745	19404	64465547
Diffuse alveolar damage	41.38	19.66	18	13763	3217	64481734
Hyperammonaemia	41.36	19.66	26	13755	9878	64475073
Pain	40.90	19.66	35	13746	553476	63931475
Cytomegalovirus test positive	39.14	19.66	20	13761	5124	64479827
Serum sickness	38.38	19.66	17	13764	3172	64481779
Disseminated intravascular coagulation	37.18	19.66	40	13741	32308	64452643
Thrombocytopenia	36.59	19.66	118	13663	223683	64261268
Chest discomfort	36.26	19.66	78	13703	116028	64368923
Kounis syndrome	36.00	19.66	16	13765	3009	64481942
Necrotising retinitis	35.84	19.66	12	13769	1051	64483900
Septic shock	35.45	19.66	73	13708	105364	64379587
Anaphylactoid reaction	34.83	19.66	18	13763	4720	64480231
Hypoxia	34.43	19.66	65	13716	88084	64396867
Tachycardia	34.23	19.66	89	13692	149490	64335461
Arthralgia	32.60	19.66	28	13753	442232	64042719
Eosinophilic pneumonia	32.53	19.66	17	13764	4560	64480391
Anaphylactic reaction	32.41	19.66	55	13726	68609	64416342
Acute coronary syndrome	31.70	19.66	29	13752	19281	64465670
Product dose omission issue	30.78	19.66	3	13778	194744	64290207
Upper respiratory tract inflammation	29.63	19.66	15	13766	3767	64481184
Cardiac ventricular disorder	29.62	19.66	8	13773	335	64484616
Pain in extremity	29.41	19.66	14	13767	303071	64181880
Dizziness	28.46	19.66	30	13751	430133	64054818
Rash	28.32	19.66	181	13600	458368	64026583
Oropharyngeal discomfort	27.41	19.66	16	13765	5319	64479632
Hyperamylasaemia	25.90	19.66	9	13772	882	64484069
Enterocolitis	25.71	19.66	21	13760	11997	64472954
Eosinophilia	25.71	19.66	36	13745	38040	64446911
Abdominal compartment syndrome	25.21	19.66	10	13771	1418	64483533
Drug intolerance	24.79	19.66	5	13776	187987	64296964
Cyanosis	24.76	19.66	27	13754	22128	64462823
Sepsis	24.66	19.66	106	13675	230235	64254716
Condition aggravated	24.60	19.66	26	13755	372400	64112551
Mucosal inflammation	24.24	19.66	46	13735	62538	64422413
Wrong patient received product	23.99	19.66	13	13768	3749	64481202
Lung disorder	23.99	19.66	45	13736	60655	64424296
Cholestasis	23.95	19.66	38	13743	44834	64440117
Hypothermia	23.60	19.66	25	13756	19831	64465120
Lymphopenia	23.16	19.66	28	13753	25629	64459322
Weight increased	22.03	19.66	9	13772	213339	64271612
Type I hypersensitivity	21.82	19.66	12	13769	3562	64481389
Abdominal discomfort	21.77	19.66	6	13775	182316	64302635
Swelling	21.68	19.66	4	13777	160214	64324737
Drug reaction with eosinophilia and systemic symptoms	21.18	19.66	40	13741	54177	64430774
Larynx irritation	21.03	19.66	5	13776	124	64484827
Psychiatric decompensation	19.98	19.66	10	13771	2453	64482498

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AB02	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
ATC	R06AB52	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dermatographic urticaria	indication	7632005	DOID:743
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic rhinitis	indication	61582004
Urticaria	indication	126485001
Seasonal allergic rhinitis	indication	367498001
Itching of skin	indication	418363000
Allergic conjunctivitis	indication	473460002	DOID:11204
Brain damage	contraindication	2470005
Ocular hypertension	contraindication	4210003	DOID:9282
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Dependent drug abuse	contraindication	6525002
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Alcohol withdrawal delirium	contraindication	8635005
Peptic ulcer	contraindication	13200003	DOID:750
Asthenia	contraindication	13791008
Severe chronic ulcerative colitis	contraindication	14311001
Constipation	contraindication	14760008	DOID:2089
Chronic disease of respiratory system	contraindication	17097001
Mood swings	contraindication	18963009
Myocardial infarction	contraindication	22298006	DOID:5844
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Ventricular tachycardia	contraindication	25569003
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hypercapnia	contraindication	29596007
Dehydration	contraindication	34095006
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Acidosis	contraindication	51387008
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Arterial thrombosis	contraindication	65198009
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Poisoning by acetaminophen	contraindication	70273001
Arteriosclerotic vascular disease	contraindication	72092001
Diabetes mellitus	contraindication	73211009	DOID:9351
Urethral stricture	contraindication	76618002
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Chronic idiopathic constipation	contraindication	82934008
Cor pulmonale	contraindication	83291003	DOID:8515
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Pulmonary emphysema	contraindication	87433001
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Acute abdominal pain	contraindication	116290004
Procedure on urinary system	contraindication	118677009
Gastrointestinal obstruction	contraindication	126765001
Neoplasm of brain	contraindication	126952004	DOID:1319
Seizure disorder	contraindication	128613002
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Drug-induced psychosis	contraindication	191483003	DOID:1742
Partial atrioventricular block	contraindication	195039008
Acute pancreatitis	contraindication	197456007	DOID:2913
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Morbid obesity	contraindication	238136002	DOID:11981
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Drowsy	contraindication	271782001
Exacerbation of asthma	contraindication	281239006
Lesion of brain	contraindication	301766008
Coma	contraindication	371632003
Primary adrenocortical insufficiency	contraindication	373662000
Operation on gastrointestinal tract	contraindication	386621005
Hypoxia	contraindication	389086002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Central nervous system depression	contraindication	418072004
Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	422681000
Dysfunction of sphincter of Oddi	contraindication	430887001
Hypertensive urgency	contraindication	443482000
Acute exacerbation of asthma	contraindication	708038006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	Basic
pKa2	4.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.14	CHEMBL	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.16	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	7.89	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.31	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.98	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.92	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.68	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.09	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.48	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.60	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.26	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.56	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.13	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.13	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	4.78	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.12	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.07	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	4.93	DRUG MATRIX

External reference:

ID	Source
D07803	KEGG_DRUG
4019712	VUID
N0000147804	NUI
2438-32-6	SECONDARY_CAS_RN
4018792	VANDF
4019712	VANDF
C0057606	UMLSCUI
CHEBI:4464	CHEBI
CHEMBL1201353	ChEMBL_ID
CHEMBL1200927	ChEMBL_ID
DB13679	DRUGBANK_ID
C018904	MESH_SUPPLEMENTAL_RECORD_UI
1210	IUPHAR_LIGAND_ID
955	INN_ID
3Q9Q0B929N	UNII
33036	PUBCHEM_CID
DB09555	DRUGBANK_ID
22697	RXNORM
1479	MMSL
4556	MMSL
d00784	MMSL
003393	NDDF
004796	NDDF
16031005	SNOMEDCT_US
372663001	SNOMEDCT_US
68680008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RYMED	HUMAN OTC DRUG LABEL	2	0485-0080	TABLET, COATED	2 mg	ORAL	OTC monograph final	16 sections
RYCLORA	HUMAN PRESCRIPTION DRUG LABEL	1	15370-150	LIQUID	2 mg	ORAL	ANDA	13 sections
Polytussin DM	HUMAN OTC DRUG LABEL	3	50991-492	SYRUP	1 mg	ORAL	OTC monograph final	13 sections
ABATUSS DMX	HUMAN OTC DRUG LABEL	3	52083-625	LIQUID	1 mg	ORAL	OTC monograph final	10 sections
DELTUSS DMX Cough Suppressant Nasal Decongestant Antihistamine GRAPE Flavor	HUMAN OTC DRUG LABEL	3	58238-225	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
DELTUSS DP Nasal Decongestant Antihistamine CHERRY Flavor	HUMAN OTC DRUG LABEL	2	58238-226	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
VANACOF	HUMAN OTC DRUG LABEL	3	58809-999	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
Rescon	HUMAN OTC DRUG LABEL	2	64543-097	TABLET, MULTILAYER	2 mg	ORAL	OTC monograph final	15 sections
POLMON	HUMAN PRESCRIPTION DRUG LABEL	1	64543-600	SOLUTION	2 mg	ORAL	ANDA	14 sections
PRO-REDAC	HUMAN OTC DRUG LABEL	3	66594-499	SYRUP	1 mg	ORAL	OTC monograph final	16 sections
chlophedianol hydrochloride, dexchlorpheniramine maleate, and pseudoephedrine hydrochloride	HUMAN OTC DRUG LABEL	3	69367-183	LIQUID	1 mg	ORAL	OTC MONOGRAPH FINAL	17 sections
WesTussin DM	HUMAN OTC DRUG LABEL	3	69367-334	SYRUP	1 mg	ORAL	OTC MONOGRAPH FINAL	17 sections